[A21-154] Sacituzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 20.05.2022
Project no.:
A21-154
Commission:
Commission awarded on 01.12.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with unresectable or metastatic triple-negative breast cancer who have had two or more prior systemic therapies including at least one of them for advanced disease
Hint of major added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-41 | Sacituzumab govitecan (breast cancer) - Addendum to Commission A21-154 | Commission completed |
| A23-86 | Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-05-20 A G-BA decision was published.